Abstract
Breast cancer is still the leading cause of cancer deaths among women worldwide and new therapies and drugs are continuously being conceived and explored to better control or even cure this disease. Among the most efficacious low-molecular drugs for the treatment of breast cancer are indole derivatives such as 3,3’-diindolylmethane (DIM), the structurally complex antimitotic vinca alkaloids, and the synthetic receptor tyrosine kinase inhibitor sunitinib. This review is to give an insight into the latest developments in the field of indole based drugs against breast cancers with a focus on those derived from natural products and on their targets and modes of action. Pertinent literature is covered from 2007 up to 2012.
Keywords: Indole, DIM, kinase inhibitors, protein binders, tubulin, anticancer drugs, breast cancer
Current Drug Targets
Title:Indole Compounds Against Breast Cancer: Recent Developments
Volume: 13 Issue: 14
Author(s): Bernhard Biersack and Rainer Schobert
Affiliation:
Keywords: Indole, DIM, kinase inhibitors, protein binders, tubulin, anticancer drugs, breast cancer
Abstract: Breast cancer is still the leading cause of cancer deaths among women worldwide and new therapies and drugs are continuously being conceived and explored to better control or even cure this disease. Among the most efficacious low-molecular drugs for the treatment of breast cancer are indole derivatives such as 3,3’-diindolylmethane (DIM), the structurally complex antimitotic vinca alkaloids, and the synthetic receptor tyrosine kinase inhibitor sunitinib. This review is to give an insight into the latest developments in the field of indole based drugs against breast cancers with a focus on those derived from natural products and on their targets and modes of action. Pertinent literature is covered from 2007 up to 2012.
Export Options
About this article
Cite this article as:
Biersack Bernhard and Schobert Rainer, Indole Compounds Against Breast Cancer: Recent Developments, Current Drug Targets 2012; 13 (14) . https://dx.doi.org/10.2174/138945012804545551
DOI https://dx.doi.org/10.2174/138945012804545551 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design Interventional Radiology in Paediatrics
Current Pediatric Reviews Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs
Current Drug Targets Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Anti-TNF and Crohns Disease: When Should We Stop?
Current Drug Targets Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity
Mini-Reviews in Medicinal Chemistry MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Lipid Oxidation Products in the Pathogenesis of Inflammation-related Gut Diseases
Current Medicinal Chemistry Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer
Current Pharmaceutical Design Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Ligand-Targeted Liposomal Therapies of Neuroblastoma
Current Medicinal Chemistry Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry